American vaccine-maker Novavax has started its early stage trial of a vaccine which combines an as-yet-unapproved Covid-19 shot with the company’s NanoFlu influenza jab.
In a statement on Wednesday, Novavax said it has initiated an early stage study, enrolling 640 healthy adults between the ages of 50 and 70, to test the safety and effectiveness of its combined influenza/Covid-19 vaccine.
Continue reading https://on.rt.com/bg8f